Key result
Postmenopausal women with breast cancer using aromatase inhibitors had significantly lower heart rate variability indices, including Mean RR and SDNN (p=0.03), compared to women without breast cancer.
Why the study?
Autonomic modulation is an important predictor of cardiovascular risk in women with breast cancer, prompting evaluation of cardiac autonomic modulation and biochemical variables in postmenopausal women using aromatase inhibitors.
Does breast cancer treatment with aromatase inhibitors alter cardiac autonomic modulation in postmenopausal women?
Observational (n=48)
Does breast cancer treatment with aromatase inhibitors alter cardiac autonomic modulation in postmenopausal women?
Answers are grounded in this paper and cite their sources.
Postmenopausal women with breast cancer using aromatase inhibitors exhibit reduced cardiac autonomic modulation, which inversely correlates with triglyceride levels, suggesting a potential mechanism for increased cardiovascular risk.
BACKGROUND: The use of autonomic modulation as a predictor of cardiovascular risk in women with breast cancer is important. OBJECTIVE: To evaluate the cardiac autonomic modulation of postmenopausal women using aromatase inhibitors for breast cancer treatment, as well as its relation with the following biochemical variables. METHODS: Postmenopausal women who did not have breast cancer (n = 33) and postmenopausal women with breast cancer (n = 15). For evaluation of the autonomic modulation the heart rate was recorded beat-to-beat for 30 minutes and the series of RR intervals obtained were used to calculate the following heart rate variability indices: Mean RR ms, SDNN (standard deviation of all normal RR intervals, expressed in milliseconds) ms, Mean HR, RMSSD (square root of the mean of the squared differences between adjacent normal RR interval) ms, NN50 (number of pairs of successive NNs that differ by more than 50 ms) count, pNN50% (proportion of NN50 divided by total number of NNs), RRtri (RR triangular), TINN (triangular interpolation of NN interval) ms, SD1 ms, SD2 ms, LF ms2, HF ms2, LH/HF ms2. The values of biochemical variables (fasting glycemia, triglycerides, HDL-cholesterol, and C-reactive protein) were analyzed by blood sample. RESULTS: Lower values of heart rate variability indices were observed in postmenopausal women with breast cancer in relation to postmenopausal women who did not have breast cancer: Mean RR (p = 0.03); SDNN (p = 0.03); RMSSD (p = 0.03); NN50 count (p = 0.03); pNN50 % (p = 0.03); RRtri (p = 0.02); SD1 (p = 0.01); SD2 (p = 0.02); LF ms2 (p = 0.01); HF ms2 (p = 0.03).There was an inversely proportional correlation between the indices SDNN, SD2, and HFms2 with triglycerides (SDNN p = 0.04; SD2 p = 0.04; HF ms2 p = 0.04). No statistically significant correlations were found between heart rate variability indices and others variables. Statistical significance was set at 5% for all analyses. CONCLUSION: Women with breast cancer present reduced autonomic modulation and in these women of heart rate variability indices are inversely correlated with triglyceride values.
No takes yet. Share an insight, caveat, or question.
Gonzaga et al. (2019) conducted an observational in Breast cancer (n=48). Breast cancer treated with aromatase inhibitors vs. Postmenopausal women without breast cancer was evaluated on Heart rate variability indices (Mean RR, SDNN, RMSSD, etc.) (p=0.03). Postmenopausal women with breast cancer using aromatase inhibitors had significantly lower heart rate variability indices, including Mean RR and SDNN (p=0.03), compared to women without breast cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: